The Claim
In adults with type 2 diabetes, treatment with IDegLira results in greater improvement in beta cell function, as measured by insulin secretion ratio and static index, compared to insulin degludec alone, and produces similar improvements in beta cell function as liraglutide alone, indicating that the combination therapy enhances endogenous insulin response to meals beyond basal insulin therapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In adults with type 2 diabetes, the combination drug IDegLira increases insulin secretion in response to meals more than insulin degludec alone, and matches the effect of liraglutide alone.
See the scientific wording
In adults with type 2 diabetes, IDegLira improves beta cell function, as measured by insulin secretion ratio and static index, compared to insulin degludec alone, with similar effects to liraglutide alone, suggesting the combination enhances endogenous insulin response to meals beyond basal insulin therapy.
A molecule that mimics a natural hormone binds to receptors on insulin-producing cells in the pancreas, causing them to release more insulin when blood sugar rises after eating. At the same time, this molecule tells other pancreatic cells to stop releasing a hormone that raises blood sugar, which helps keep glucose levels stable after meals.
What the research says
1 studyIDegLira helps the pancreas release more of its own insulin after meals than insulin alone, and works just as well as liraglutide alone — meaning it helps the body make more insulin naturally when you eat.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.